Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE
- PMID: 20554028
- DOI: 10.1016/j.jneuroim.2010.04.022
Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE
Abstract
The aim of this study was to identify cell populations relevant to pathogenesis and repair within the injured CNS in mice that recovered from experimental autoimmune encephalomyelitis (EAE). We demonstrate that in two EAE models, with either relapsing-remitting or chronic course, T-cells and resident activated microglia manifested extensive IL-17 expression, with apparent localization within regions of myelin loss. In mice treated with glatiramer acetate (GA, Copaxone), even when treatment started after disease exacerbation, CNS inflammation and Th-17 occurrence were drastically reduced, with parallel elevation in T-regulatory cells, indicating the immunomodulatory therapeutic consequences of GA treatment in situ.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.J Autoimmun. 2011 Nov;37(3):228-41. doi: 10.1016/j.jaut.2011.06.003. Epub 2011 Jul 14. J Autoimmun. 2011. PMID: 21752599
-
Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.J Immunol. 2011 Feb 15;186(4):1887-90. doi: 10.4049/jimmunol.1090138. J Immunol. 2011. PMID: 21289312 Review.
-
T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice.J Neuroimmunol. 2004 Mar;148(1-2):1-10. doi: 10.1016/j.jneuroim.2003.10.057. J Neuroimmunol. 2004. PMID: 14975581
-
Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.J Neurosci Res. 2005 Mar 1;79(5):680-93. doi: 10.1002/jnr.20377. J Neurosci Res. 2005. PMID: 15682385
-
Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.J Autoimmun. 2014 Nov;54:81-92. doi: 10.1016/j.jaut.2014.05.005. Epub 2014 Jun 14. J Autoimmun. 2014. PMID: 24934599 Review.
Cited by
-
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Int J Mol Sci. 2012 Oct 4;13(10):12665-709. doi: 10.3390/ijms131012665. Int J Mol Sci. 2012. PMID: 23202920 Free PMC article. Review.
-
Repurposing of glatiramer acetate to treat cardiac ischemia in rodent models.Nat Cardiovasc Res. 2024 Sep;3(9):1049-1066. doi: 10.1038/s44161-024-00524-x. Epub 2024 Aug 26. Nat Cardiovasc Res. 2024. PMID: 39215106
-
Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses.Arch Virol. 2018 May;163(5):1279-1284. doi: 10.1007/s00705-018-3729-6. Epub 2018 Jan 23. Arch Virol. 2018. PMID: 29362931 Free PMC article.
-
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.CNS Neurol Disord Drug Targets. 2017;16(6):714-723. doi: 10.2174/1871527316666170223162747. CNS Neurol Disord Drug Targets. 2017. PMID: 28240190 Free PMC article.
-
Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS.Neurol Neuroimmunol Neuroinflamm. 2020 Mar 17;7(3):e698. doi: 10.1212/NXI.0000000000000698. Print 2020 May. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32184341 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources